IL272747B2 - Bispecific 2 + 1 contorsbodies - Google Patents
Bispecific 2 + 1 contorsbodiesInfo
- Publication number
- IL272747B2 IL272747B2 IL272747A IL27274720A IL272747B2 IL 272747 B2 IL272747 B2 IL 272747B2 IL 272747 A IL272747 A IL 272747A IL 27274720 A IL27274720 A IL 27274720A IL 272747 B2 IL272747 B2 IL 272747B2
- Authority
- IL
- Israel
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr
- variable region
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (25)
1. A bispecific antibody consisting of two fusion polypeptides and comprising two conventional Fabs capable of specific binding to a first target and one cross-Fab capable of specific binding to a second target comprising (a) a first fusion polypeptide comprising an antibody heavy chain Fab fragment (VH-CH1) capable of specific binding to the first target, a spacer domain, a antibody light chain Fab fragment (VL-Ckappa) capable of specific binding to the first target and an antibody cross-Fab fragment comprising VH-Ckappa capable of specific binding to the second target, wherein - the spacer domain comprises an antibody hinge region or a fragment thereof and an IgG1 Fc domain, - the antibody heavy chain Fab fragment (VH-CH1)capable of specific binding to the first target is fused either directly or via a first peptide linker to the N-terminus of the spacer domain, - the antibody light chain Fab fragment (VL-Ckappa) capable of specific binding to the first target is fused either directly or via a second peptide linker to the C-terminus of the spacer domain, and - the first part of an antibody cross-Fab fragment (VH-Ckappa)capable of specific binding to a second target is fused either directly or via a third peptide linker to the C-terminus of the antibody light chain Fab fragment (VL-Ckappa)capable of specific binding to the first target or is fused either directly or via a third peptide linker to the N-terminus of the antibody heavy chain Fab fragment (VH-CH1)capable of specific binding to the first target, and (b) a second fusion polypeptide comprising a first part of a second antibody heavy chain Fab fragment (VH-CH1) capable of specific binding to a first target, a spacer domain, a second antibody light chain Fab fragment (VL-Ckappa) capable of specific binding to a first target and an antibody cross-Fab fragment comprising VL-CH1 capable of specific binding to a second target, wherein - the spacer domain comprises an antibody hinge region or a fragment thereof and an IgG1 Fc domain, - the second antibody heavy chain Fab fragment (VH-CH1)capable of specific binding to a first target is fused either directly or via a first peptide linker to the N-terminus of the spacer domain, 272747/-173- - the second antibody light chain Fab fragment (VL-Ckappa)capable of specific binding to a first target is fused either directly or via a second peptide linker to the C-terminus of the spacer domain, and - the antibody cross-Fab fragment comprising VL-CH1 capable of specific binding to a second target is fused either directly or via a third peptide linker to the C-terminus of the second antibody light chain Fab fragment (VL-Ckappa) capable of specific binding to a first target or is fused either directly or via a third peptide linker to the N-terminus of the second antibody heavy chain Fab fragment (VH-CH1)capable of specific binding to a first target, and wherein the antibody cross-Fab fragment comprising VH-Ckappa and the antibody cross-Fab fragment comprising VL-CH1 capable of specific binding to the second target are associated with each other to form the cross-Fab capable of specific binding to the second target and wherein the first part and the second part of the first and second conventional Fab capable of specific binding to the first target are associated with each other to form a circular fusion polypeptide, and wherein the spacer domain of the first fusion polypeptide and the spacer domain of the second fusion polypeptide are associated covalently to each other by a disulfide bond and comprise knob-into-hole modifications promoting the association of the first and second fusion polypeptide.
2. The bispecific antibody of claims 1, wherein the third peptide linker connecting the first part or the second part of an antigen binding domain capable of specific binding to a second target comprises at least 15 amino acids.
3. The bispecific antibody of claims 1 or 2, wherein the spacer domain of the first fusion polypeptide comprises holes and the spacer domain of the second fusion polypeptide comprises knobs according to the knobs into hole method.
4. The bispecific antibody of any one of claims 1 to 3, wherein the IgG1 Fc domain comprises amino acid substitutions L234A, L235A and P329G (numbering according to Kabat EU index).
5. The bispecific antibody of any one of claims 1 to 4, wherein the antigen binding domain capable of specific binding to a second target is an antigen binding domain capable of specific binding to a tumor associated antigen.
6. The bispecific antibody of any one of claims 1 to 5, wherein the antigen binding domain capable of specific binding to a second target is an antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP). 272747/-174-
7. The bispecific antibody of any one of claims 1 to 6, wherein the antigen binding domain capable of specific binding to FAP comprises (a) a heavy chain variable region (VHFAP) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3, and a light chain variable region (VLFAP) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6, or (b) a heavy chain variable region (VHFAP) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:9, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:10, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:11, and a light chain variable region (VLFAP) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:12, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:13, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:14.
8. The bispecific antibody of any one of claims 1 to 7, wherein the antigen binding domain capable of specific binding to FAP comprises (a) a heavy chain variable region (VHFAP) comprising an amino acid sequence of SEQ ID NO:7, and a light chain variable region (VLFAP) comprising an amino acid sequence of SEQ ID NO:8, or (b) a heavy chain variable region (VHFAP) comprising an amino acid sequence of SEQ ID NO:15, and a light chain variable region (VLFAP) comprising an amino acid sequence of SEQ ID NO:16.
9. The bispecific antibody of any one of claims 1 to 8, wherein the antigen binding domain capable of specific binding to a first target is an antigen binding domain capable of specific binding to OX40.
10. The bispecific antibody of any one of claims 1 to 9, wherein the antigen binding domain capable of specific binding to OX40 comprises (a) a heavy chain variable region (VHOX40) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:17, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:19, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:22, and a light chain variable region (VLOX40) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:28, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:31, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:35, or (b) a heavy chain variable region (VHOX40) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:17, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:19, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:21, and a 272747/-175- light chain variable region (VLOX40) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:28, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:31, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:34, or (c) a heavy chain variable region (VHOX40) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:17, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:19, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:23, and a light chain variable region (VLOX40) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:28, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:31, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:36, or (d) a heavy chain variable region (VHOX40) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:17, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:19, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:24, and a light chain variable region (VLOX40) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:28, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:31, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:37, or (e) a heavy chain variable region (VHOX40) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:18, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:20, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:25, and a light chain variable region (VLOX40) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:29, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:32, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:38, or (f) a heavy chain variable region (VHOX40) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:18, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:20, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:26, and a light chain variable region (VLOX40) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:29, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:32, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:38, or (g) a heavy chain variable region (VHOX40) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:18, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:20, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:27, and a light chain variable region (VLOX40) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:30, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:33, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:39.
11. The bispecific antibody of any one of claims 1 to 10, wherein the antigen binding domain capable of specific binding to OX40 comprises (a) a heavy chain variable region (VHOX40) comprising an amino acid sequence of SEQ ID NO:40 and a light chain variable region (VLOX40) comprising an amino acid sequence of 272747/-176- SEQ ID NO:41, or (b) a heavy chain variable region (VHOX40) comprising an amino acid sequence of SEQ ID NO:42 and a light chain variable region (VLOX40) comprising an amino acid sequence of SEQ ID NO:43, or (c) a heavy chain variable region (VHOX40) comprising an amino acid sequence of SEQ ID NO:44 and a light chain variable region (VLOX40) comprising an amino acid sequence of SEQ ID NO:45, or (d) a heavy chain variable region (VHOX40) comprising an amino acid sequence of SEQ ID NO:46 and a light chain variable region (VLOX40) comprising an amino acid sequence of SEQ ID NO:47, or (e) a heavy chain variable region (VHOX40) comprising an amino acid sequence of SEQ ID NO:48 and a light chain variable region (VLOX40) comprising an amino acid sequence of SEQ ID NO:49, or (f) a heavy chain variable region (VHOX40) comprising an amino acid sequence of SEQ ID NO:50 and a light chain variable region (VLOX40) comprising an amino acid sequence of SEQ ID NO:51, or (g) a heavy chain variable region (VHOX40) comprising an amino acid sequence of SEQ ID NO:52 and a light chain variable region (VLOX40) comprising an amino acid sequence of SEQ ID NO:53.
12. The bispecific antibody of any one of claims 1 to 11, wherein the antigen binding domain capable of specific binding to OX40 comprises a heavy chain variable region (VHOX40) comprising an amino acid sequence of SEQ ID NO:40, and a light chain variable region (VLOX40) comprising an amino acid sequence of SEQ ID NO:41.
13. The bispecific antibody of any one of claims 1 to 8, wherein the antigen binding domain capable of specific binding to a first target is an antigen binding domain capable of specific binding to 4-1BB.
14. The bispecific antibody of any one of claims 1 to 8 or 13, wherein the antigen binding domain capable of specific binding to 4-1BB comprises a heavy chain variable region (VH4-1BB) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:135, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:136, and (iii) CDR-Hcomprising the amino acid sequence of SEQ ID NO:137, and a light chain variable region (VL4-1BB) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:138, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:139, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:140. 35 272747/-177-
15. The bispecific antibody of any one of claims 1 to 8 or 13 or 14, wherein the antigen binding domain capable of specific binding to 4-1BB comprises a heavy chain variable region (VH4-1BB) comprising an amino acid sequence of SEQ ID NO:141, and a light chain variable region (VL4-1BB) comprising an amino acid sequence of SEQ ID NO:142.
16. The bispecific antibody of any one of claims 1 to 8, wherein the antigen binding domain capable of specific binding to a first target is an antigen binding domain capable of specific binding to CD40.
17. The bispecific antibody of any one of claims 1 to 8 or 16, wherein the antigen binding domain capable of specific binding to CD40 comprises a heavy chain variable region (VHCD40) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:147, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:148, and (iii) CDR-Hcomprising the amino acid sequence of SEQ ID NO:149, and a light chain variable region (VLCD40) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:150, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:151, and (vi) CDR-Lcomprising the amino acid sequence of SEQ ID NO:152.
18. The bispecific antibody of any one of claims 1 to 8 or 16 or 17, wherein the antigen binding domain capable of specific binding to CD40 comprises a heavy chain variable region (VHCD40) comprising an amino acid sequence of SEQ ID NO:153, and a light chain variable region (VLCD40) comprising an amino acid sequence of SEQ ID NO:154.
19. The bispecific antibody of any one of claims 1 to 8 or 16 or 17, wherein the antigen binding domain capable of specific binding to a first target is an antigen binding domain capable of specific binding to CD40 comprises (i) a heavy chain variable region (VHCD40) comprising an amino acid sequence selected from the group consisting of SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169 and SEQ ID NO:170, and a light chain variable region (VLCD40) comprising the amino acid sequence selected from the group consisting of SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, and SEQ ID NO:174, or (ii) a heavy chain variable region (VHCD40) comprising an amino acid sequence selected from the group consisting of SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179 and SEQ ID NO:180, and a light chain variable region (VLCD40) comprising the amino acid sequence selected from the group consisting of SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, and SEQ ID NO:184.
20. Isolated nucleic acid encoding the bispecific antibody of any one of claims 1 to 19. 272747/-178-
21. A vector or host cell comprising the nucleic acid of claim 20.
22. A method of producing a bispecific antibody culturing the host cell of claim 21 under conditions suitable for the expression of the bispecific antibody.
23. A pharmaceutical composition comprising the bispecific antibody of any one of claims 1 to and a pharmaceutically acceptable excipient.
24. The bispecific antibody of any one of claims 1 to 19 or the pharmaceutical composition of claim 23 for use as medicament.
25. The bispecific antibody of any one of claims 1 to 19 or the pharmaceutical composition of claim 23 for use in treating cancer or infectious diseases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17199537 | 2017-11-01 | ||
| PCT/EP2018/079785 WO2019086500A2 (en) | 2017-11-01 | 2018-10-31 | Bispecific 2+1 contorsbodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL272747A IL272747A (en) | 2020-04-30 |
| IL272747B1 IL272747B1 (en) | 2024-12-01 |
| IL272747B2 true IL272747B2 (en) | 2025-04-01 |
Family
ID=60201893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL272747A IL272747B2 (en) | 2017-11-01 | 2018-10-31 | Bispecific 2 + 1 contorsbodies |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12227594B2 (en) |
| EP (1) | EP3703821A2 (en) |
| JP (1) | JP7098725B2 (en) |
| KR (1) | KR20200079492A (en) |
| CN (1) | CN111182944B (en) |
| AU (1) | AU2018357923A1 (en) |
| BR (1) | BR112020006443A2 (en) |
| CA (1) | CA3076027A1 (en) |
| CL (1) | CL2020000662A1 (en) |
| CR (1) | CR20200171A (en) |
| IL (1) | IL272747B2 (en) |
| MA (1) | MA50505A (en) |
| MX (1) | MX2020004571A (en) |
| MY (1) | MY205342A (en) |
| PE (1) | PE20210844A1 (en) |
| SG (1) | SG11202002903XA (en) |
| TW (1) | TWI829658B (en) |
| WO (1) | WO2019086500A2 (en) |
| ZA (1) | ZA202001139B (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2788979T3 (en) | 2014-11-14 | 2020-10-23 | Hoffmann La Roche | Antigen-binding molecules comprising a ligand trimer of the TNF family |
| JP6996979B2 (en) | 2015-03-31 | 2022-02-04 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Antigen-binding molecule containing trimer TNF family ligand |
| MY206406A (en) | 2015-10-02 | 2024-12-16 | Hoffmann La Roche | Bispecific antibodies specific for a costimulatory tnf receptor |
| JP6675017B2 (en) * | 2016-05-02 | 2020-04-01 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Contrast body-single chain target binding substance |
| JP7125400B2 (en) | 2016-12-19 | 2022-08-24 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Combination therapy with targeted 4-1BB (CD137) agonists |
| KR102692708B1 (en) | 2016-12-20 | 2024-08-07 | 에프. 호프만-라 로슈 아게 | Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists |
| CA3047070A1 (en) | 2017-01-03 | 2018-07-12 | F.Hoffmann-La Roche Ag | Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9 |
| WO2018178055A1 (en) * | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
| WO2018178076A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
| KR102461885B1 (en) | 2017-04-03 | 2022-11-03 | 에프. 호프만-라 로슈 아게 | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
| CN110402255B (en) | 2017-04-04 | 2022-12-02 | 豪夫迈·罗氏有限公司 | A novel bispecific antigen-binding molecule capable of specifically binding CD40 and FAP |
| BR112020008031A2 (en) * | 2017-11-01 | 2020-10-27 | F. Hoffmann-La Roche Ag | multispecific antibody, method for preparing multispecific antibody, set of nucleic acids, expression vector, host cell and pharmaceutical composition |
| WO2019136405A1 (en) | 2018-01-05 | 2019-07-11 | City Of Hope | Multi-specific ligand binders |
| TWI841551B (en) | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | Combination therapy with targeted 4-1bb (cd137) agonists |
| CR20200459A (en) | 2018-04-13 | 2020-11-11 | Hoffmann La Roche | Her2-targeting antigen binding molecules comprising 4-1bbl |
| US11242396B2 (en) | 2018-10-01 | 2022-02-08 | Hoffmann-La Roche Inc. | Bispecific antigen binding molecules comprising anti-FAP clone 212 |
| CR20210326A (en) | 2018-12-21 | 2021-09-10 | Hoffmann La Roche | CD28 ANTIGEN BINDING AGONIST MOLECULES ACTING ON THE TUMOR |
| EP3959237A1 (en) * | 2019-04-25 | 2022-03-02 | F. Hoffmann-La Roche AG | Therapeutic multispecific polypeptides activated by polypeptide chain exchange |
| JP7812230B2 (en) * | 2019-04-25 | 2026-02-09 | エフ. ホフマン-ラ ロシュ アーゲー | Generation of antibody-derived polypeptides by polypeptide chain exchange |
| AU2020263910A1 (en) * | 2019-04-25 | 2021-10-21 | F. Hoffmann-La Roche Ag | Activatable therapeutic multispecific polypeptides with extended half-life |
| CA3140385A1 (en) * | 2019-05-15 | 2020-11-19 | Kyowa Kirin Co., Ltd. | Bispecific antibody binding to cd40 and fap |
| EP3990492A1 (en) * | 2019-06-27 | 2022-05-04 | F. Hoffmann-La Roche AG | Novel icos antibodies and tumor-targeted antigen binding molecules comprising them |
| AR121706A1 (en) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | OX40 AND FAP-TARGETED BSPECIFIC ANTIGEN-BINDING MOLECULES |
| JP2023504675A (en) * | 2020-05-19 | 2023-02-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Binding molecules for cancer treatment |
| CR20240246A (en) * | 2021-12-20 | 2024-07-19 | Hoffmann La Roche | AGONIST ANTI-LTBR ANTIBODIES AND BISPECIFIC ANTIBODIES THAT INCLUDE THEM |
| EP4540290A4 (en) * | 2022-06-14 | 2026-07-01 | Invenra Inc | Multispecific binders targeting B7H3 and GD2 and uses thereof |
| JP2025528212A (en) * | 2022-08-18 | 2025-08-26 | イムノコア リミテッド | Multidomain binding molecules |
| US20260193634A1 (en) * | 2022-11-10 | 2026-07-09 | The Johns Hopkins University | System For Modulating Receptor Tyrosine Kinase Signaling And Methods Of Use Thereof |
| TW202436358A (en) * | 2023-03-01 | 2024-09-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Fap/4-1bb/cd40 binding molecules and pharmaceutical uses thereof |
| TW202540200A (en) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | Anti-fap-light fusion protein and use thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012020006A2 (en) * | 2010-08-13 | 2012-02-16 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
| WO2014116846A2 (en) * | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| WO2017060144A1 (en) * | 2015-10-07 | 2017-04-13 | F. Hoffmann-La Roche Ag | Bispecific antibodies with tetravalency for a costimulatory tnf receptor |
| WO2017180913A2 (en) * | 2016-04-13 | 2017-10-19 | Sanofi | Trispecific and/or trivalent binding proteins |
| WO2017191101A1 (en) * | 2016-05-02 | 2017-11-09 | F. Hoffmann-La Roche Ag | The contorsbody - a single chain target binder |
| WO2018127473A1 (en) * | 2017-01-03 | 2018-07-12 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9 |
| WO2018185045A1 (en) * | 2017-04-04 | 2018-10-11 | F. Hoffmann-La Roche Ag | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2808353C2 (en) | 1977-04-18 | 1984-01-19 | Hitachi Metals, Ltd., Tokyo | Earring |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| FI903489A7 (en) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligands containing one moiety, receptors containing these ligands, methods for their preparation and uses of the ligands and receptors |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572L (en) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Combination and method of use of anti-erbB-2 monoclonal antibodies |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| JP2002506353A (en) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | Methods and compositions for galactosylated glycoproteins |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| DE19742706B4 (en) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | lipocalin muteins |
| CA2307166A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| JP4334141B2 (en) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | Engineering glycosylation of antibodies to improve antibody-dependent cytotoxicity |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| KR100797667B1 (en) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | How to regulate transcription of foreign genes |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| CN1294148C (en) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | Single-stranded cyctic trispecific antibody |
| EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
| PL213948B1 (en) | 2001-10-25 | 2013-05-31 | Genentech Inc | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| RS20150135A1 (en) | 2003-05-30 | 2015-08-31 | Genentech Inc. | TREATMENT WITH ANTI-VEGF ANTIBODIES |
| CA2531238C (en) | 2003-07-04 | 2015-02-24 | Affibody Ab | Polypeptides having binding affinity for her2 |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| CN1326881C (en) | 2003-09-29 | 2007-07-18 | 中国人民解放军军事医学科学院基础医学研究所 | Trivalent bispecific antibody and its preparation process and use |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| HUE038955T2 (en) | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigen binding molecules with increased Fc receptor binding affinity and effector function |
| BRPI0417302A (en) | 2003-12-05 | 2007-03-06 | Compound Therapeutics Inc | type 2 vascular endothelial growth factor receptor inhibitors |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| TR201808537T4 (en) | 2004-09-23 | 2018-07-23 | Genentech Inc | Cysteine modified antibodies and conjugates. |
| JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
| KR101374454B1 (en) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | Methods for producing polypeptides by regulating polypeptide association |
| JP5027804B2 (en) | 2005-05-26 | 2012-09-19 | シアトル ジェネティクス,インコーポレーテッド | Humanized anti-CD40 antibodies and methods of use thereof |
| DK1999154T3 (en) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | MANUFACTURED HETERODIMERED PROTEIN DOMAINS |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| ES2579231T3 (en) | 2008-01-15 | 2016-08-08 | Abbvie Inc | Enhanced mammalian expression vectors and uses thereof |
| PT2417156E (en) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Trivalent, bispecific antibodies |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| CN103429620B (en) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | Antibody design for stable heterodimerization with mutations in the Fc domain |
| LT2691417T (en) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antibody fc variants |
| WO2013006244A1 (en) * | 2011-06-08 | 2013-01-10 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Bispecific monoclonal antibody therapeutics against west nile virus with improved cns penetration |
| EP2729488A4 (en) | 2011-07-06 | 2015-01-14 | Medimmune Llc | Methods for making multimeric polypeptides |
| JP6038920B2 (en) | 2011-08-23 | 2016-12-07 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Anti-OX40 antibody and method of using the same |
| US9527927B2 (en) | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| MY206406A (en) | 2015-10-02 | 2024-12-16 | Hoffmann La Roche | Bispecific antibodies specific for a costimulatory tnf receptor |
| BR112020008031A2 (en) | 2017-11-01 | 2020-10-27 | F. Hoffmann-La Roche Ag | multispecific antibody, method for preparing multispecific antibody, set of nucleic acids, expression vector, host cell and pharmaceutical composition |
-
2018
- 2018-10-31 PE PE2020000390A patent/PE20210844A1/en unknown
- 2018-10-31 MY MYPI2020002151A patent/MY205342A/en unknown
- 2018-10-31 MA MA050505A patent/MA50505A/en unknown
- 2018-10-31 BR BR112020006443-2A patent/BR112020006443A2/en not_active Application Discontinuation
- 2018-10-31 IL IL272747A patent/IL272747B2/en unknown
- 2018-10-31 MX MX2020004571A patent/MX2020004571A/en unknown
- 2018-10-31 EP EP18800546.6A patent/EP3703821A2/en active Pending
- 2018-10-31 CA CA3076027A patent/CA3076027A1/en active Pending
- 2018-10-31 WO PCT/EP2018/079785 patent/WO2019086500A2/en not_active Ceased
- 2018-10-31 KR KR1020207011913A patent/KR20200079492A/en not_active Ceased
- 2018-10-31 CN CN201880063441.2A patent/CN111182944B/en active Active
- 2018-10-31 SG SG11202002903XA patent/SG11202002903XA/en unknown
- 2018-10-31 US US16/760,820 patent/US12227594B2/en active Active
- 2018-10-31 AU AU2018357923A patent/AU2018357923A1/en not_active Abandoned
- 2018-10-31 TW TW107138691A patent/TWI829658B/en active
- 2018-10-31 JP JP2020523704A patent/JP7098725B2/en active Active
- 2018-10-31 CR CR20200171A patent/CR20200171A/en unknown
-
2020
- 2020-02-24 ZA ZA2020/01139A patent/ZA202001139B/en unknown
- 2020-03-13 CL CL2020000662A patent/CL2020000662A1/en unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012020006A2 (en) * | 2010-08-13 | 2012-02-16 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
| WO2014116846A2 (en) * | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| WO2017060144A1 (en) * | 2015-10-07 | 2017-04-13 | F. Hoffmann-La Roche Ag | Bispecific antibodies with tetravalency for a costimulatory tnf receptor |
| WO2017180913A2 (en) * | 2016-04-13 | 2017-10-19 | Sanofi | Trispecific and/or trivalent binding proteins |
| WO2017191101A1 (en) * | 2016-05-02 | 2017-11-09 | F. Hoffmann-La Roche Ag | The contorsbody - a single chain target binder |
| WO2018127473A1 (en) * | 2017-01-03 | 2018-07-12 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9 |
| WO2018185045A1 (en) * | 2017-04-04 | 2018-10-11 | F. Hoffmann-La Roche Ag | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020117441A (en) | 2021-12-01 |
| MA50505A (en) | 2020-09-09 |
| IL272747A (en) | 2020-04-30 |
| EP3703821A2 (en) | 2020-09-09 |
| KR20200079492A (en) | 2020-07-03 |
| TW201922791A (en) | 2019-06-16 |
| TWI829658B (en) | 2024-01-21 |
| CA3076027A1 (en) | 2019-05-09 |
| US12227594B2 (en) | 2025-02-18 |
| CN111182944B (en) | 2022-11-22 |
| PE20210844A1 (en) | 2021-05-10 |
| BR112020006443A2 (en) | 2020-09-29 |
| MX2020004571A (en) | 2020-08-24 |
| WO2019086500A3 (en) | 2019-08-29 |
| MY205342A (en) | 2024-10-16 |
| IL272747B1 (en) | 2024-12-01 |
| JP2021500898A (en) | 2021-01-14 |
| CR20200171A (en) | 2020-06-14 |
| SG11202002903XA (en) | 2020-04-29 |
| CN111182944A (en) | 2020-05-19 |
| CL2020000662A1 (en) | 2020-10-02 |
| JP7098725B2 (en) | 2022-07-11 |
| RU2020117441A3 (en) | 2022-04-01 |
| WO2019086500A2 (en) | 2019-05-09 |
| ZA202001139B (en) | 2021-03-31 |
| AU2018357923A1 (en) | 2020-03-05 |
| US20210324108A1 (en) | 2021-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272747B1 (en) | Bispecific 2 + 1 contorsbodies | |
| JP2022512234A5 (en) | ||
| AU2020273356A1 (en) | Multispecific antibodies | |
| RU2019134352A (en) | NEW BISPECIFIC ANTIGEN-BINDING MOLECULES WITH THE ABILITY TO BIND SPECIFICALLY WITH CD40 AND FAP | |
| RU2018143439A (en) | ANTIGEN-BINDING MOLECULES CONTAINING TRIMER LIGAND OF TNF FAMILY AND PD1-BINDING Fragment | |
| JP2020536543A5 (en) | ||
| RU2019123613A (en) | BISPECIFIC ANTIGENBINDING MOLECULES CONTAINING ANTIBODY K4-1BB, CLONE 20N4.9 | |
| HRP20241775T1 (en) | BISPECIFIC ANTIBODIES THAT SPECIFICALLY BIND TO PD1 AND LAG3 | |
| JP2018537966A5 (en) | ||
| MX2011013616A (en) | Bispecific, tetravalent antigen binding proteins. | |
| GB2597851A (en) | Antibody molecules that bind to NKP30 and uses thereof | |
| RU2016145277A (en) | ANTIBODY AGAINST IGF-1R AND ITS APPLICATION AS AN ADDRESSING CARRIER FOR TREATMENT OF CANCER | |
| WO2013064701A2 (en) | Bispecific antibodies and methods for isolating same | |
| JP2025160226A5 (en) | ||
| US20240368311A1 (en) | Bispecific antigen binding construct | |
| WO2016087650A1 (en) | Domain-exchanged antibody | |
| JP2023511376A5 (en) | ||
| WO2025041097A1 (en) | Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof | |
| JPWO2022102768A5 (en) | ||
| CA2538725A1 (en) | Nogo-a binding molecules and pharmaceutical use thereof | |
| RU2025100420A (en) | FUSION PROTEINS FOLLYSTATIN-FC | |
| JP2025511000A5 (en) | ||
| WO2024188319A1 (en) | Anti-muc17, anti-cd3 and anti-cd28 trispecific antibody | |
| NZ767674A (en) | Antigen binding molecules comprising a tnf family ligand trimer | |
| NZ779636A (en) | Claudin-6 antibodies and drug conjugates |